BPDCN is a rare and clinically challenging hematologic malignancy; however, a breakthrough has been made by detecting CD123, a surface receptor for IL-3, which was overexpressed in the tumor cell. The gene discussed is IL3; the disease is CD4+/CD56+ hematodermic neoplasm.